$EXAS Stock Update

EXAS is back to roughly where it was last month after retreating following posting a larger loss than expected (-.19 vs -.18). According to management the clinical trial for Cologuard remains on track and the company remains focused on the 2012 priorities of making the FDA submission, and continuing the manufacturing and marketing preparation.

My sentiment regarding this stock continues to be Hold.

Leave a Comment